RecruitingNCT05008276

Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)

PANTHER Study: Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress


Sponsor

Petter Bjornstad

Enrollment

100 participants

Start Date

Sep 27, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better understanding of the impact of puberty on kidney health is needed to promote preservation of native kidney function, especially in youth with T2D.


Eligibility

Min Age: 8 YearsMax Age: 14 Years

Plain Language Summary

Simplified for easier understanding

This study examines how puberty affects kidney health in young people at high risk for developing Type 2 diabetes — particularly those who are overweight or have elevated blood sugar — compared to healthy peers. The goal is to understand whether the physical stress of puberty harms kidney function in at-risk youth. **You may be eligible if...** - You are in the high-risk group: your HbA1c (a blood sugar marker) is 6.0% or above, and/or your BMI is at or above the 85th percentile for your age - OR you are a healthy control participant with a normal HbA1c (≤5.6%) - You do not have Type 1 Diabetes antibodies **You may NOT be eligible if...** - You have existing chronic or acute kidney disease - You have a metabolic disorder that prevents safe fasting - You are pregnant - You have iodine or penicillin allergies - You have a blood clotting disorder or cannot have an MRI Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAminohippurate Sodium Inj 20%

Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)

DRUGIohexol Inj 300 MG/ML

Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

DRUGDextran 40

Diagnostic aid/agent used to measure glomerular size and selectivity


Locations(2)

Children's Hospital Colorado

Aurora, Colorado, United States

Seattle Children's Hospital

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05008276


Related Trials